Amblyotech Corporate Presentation from OIS@AAO 2015

1. CORPORATE PRESENTATION

2. Forward Looking
Statements
This presentation may contain forward-looking
statements. Forward-looking statements involve
known and unknown risks and uncertainties, which
could cause the Company’s actual results to differ
materially from those in the forward looking
statements. Further, this presentation does not
represent an offer to sell or the solicitation of an offer
to buy any securities. Offers and sales, if any, will be
made only pursuant to definitive documents to
qualified investors.
2

3. Amblyopia affects 3% of the
Global population
3

4. 4
How Patients With
Amblyopia View The World
Double Images Amblyopic Eye
Dominant Eye

5. The Amblyopia Market Is Large
With Little Treatment Success
From Current Options
5
• 3% of the global population suffers from amblyopia (210 million people)
• 9 million people in the US
• 2.3 million pediatric patients (patching is only 25% successful in
children)
• 6.7 million adult patients (currently no treatment options available)
• There is only a 25% rate of successful treatment
• Only 50% of patients respond to patching
• 50% of patients that respond to patching experience amblyopia relapse
within a few months
• Currently no treatment options available to adults for adults (6.7 million
adults with amblyopia in the US alone)

6. Current Treatment Options are
Sub-optimal
Current treatment options include:
• Patching
• Atropine Drops
• Surgery
6
Most common complaints:
• Ineffective
• Compliance
• Length of time to treat
• Relapse

7. 7
DIG RUSH
The first video game specifically designed to treat
Amblyopia using the patented Binocuclear Technology.

8. • Amblyotech’s Binocuclear technology provides visual stimulus to both
eyes at the same time resulting in greater clinical efficacy
• Patching, Atropine and Surgery only address monocular vision
• Amblyotech’s treatment approach works on the visual cortex by
requiring the brain to accept visual information from both eyes in order
to be successful with the game.
• Patients obtain a BINOCULAR solution and the establishment of 3-
D vision
• 95% efficacy measured by significant improvement in visual
acuity treating one hour a day for six weeks (patching requires
at least six month of compliance)
• Resulting in no relapse
8
Binocuclear: A Binocular Advantage

9. Ease of Use Enhances
Compliance
•Amblyotech has developed a novel electronic
application that can be used on an tablet,
computer or smart phone.
•Patients initially visit a clinic where their vision is
assessed and individual parameters are determined
to optimize the Ambloytech treatment.
•The device is calibrated for severity (each patient is
unique).
•Patients then proceed with the actual therapeutic
treatment on their own, using our device, which
consists of a Tablet (IPad, etc.) running a specially
modified game application.
9

10. Benefits of the Binocuclear
Treatment
•Benefits vs. Patch: Unlike the patching method, the
Ambloytech application optimizes visual acuity using both
eyes and thus prevents relapse. The Amblyotech
application can be taken anywhere without incurring the
social stigma of wearing a patch and thus provides better
patient compliance resulting in a greater therapeutic
response.
•Benefits to Adults: Current treatment methods are not
effective for adults. Adults whose vision is not corrected in
childhood or are diagnosed later in life are not provided with
any additional effective treatment options. The Amblyotech
device creates an entirely new treatment option for adult
patients.
10

11. Existing Proof of Concept: 232 Patients
Studied to Date with No Cases of Relapse
Author- Patient Age Publications Number of Patients
Hess et al
2010 & 2010b +2011 review
Adults
Optometry and Vision Science 2010; Restor Neurol Neurosci
2010; Strabismus 2011
9
Knox et al 2012
5-14 years old
Investigative Ophthalmology & Visual Science 14
Author – Patient age range Current Biology 2012 18
Hess et al
2010 & 2010b +2011 review
Adults
IEEE 2011
Optometry 2012
10
Li et al ARVO 2013; manuscript in review
4-12y
Under Review 75
Birch et al AAPOS 2014; manuscript in review
3 - <7y
Under Review 50
Mansouri
Strabismus
2014
5-70yrs
Strabismus
2014
22
Hess 2014
adults
Clinical and Experimental Optometry 14
Spiegel 2013
Adults
Neurorehab
Neural repair
2013
16
Spiegel
2013
Under Review 4
11

12. Binocuclear Therapy Provides
Greater Results – Adult Patients
•Adult amblyopic patients do not respond to conventional therapy (i.e. eye patching).
•18 adults with Amblyopia participated in a crossover study to measure the
differences between patients treated with monocular learning (current treatment)
and dichoptic learning (the Amblyotech method).
• Dichoptic learning resulted in better efficacy compared to monocular learning.
12
Monocular Learning- only focused
on strengthening the weak eye, i.e.
patching
Dichoptic Learning-
Simultaneous training of
both eyes

13. Intellectual Property
Two US patents have been issued, which protect both our approach to
treating Amblyopia, as well as the idea of a mobile device or gaming platform
which is used for assessing and treating Amblyopia:
US patent 8,057,036: broad coverage for the method of treatment by
using different images to each of the patients eyes in conjunction with
dichoptic display system.
US patent 8,066,372: broad coverage for the use of a mobile device,
gaming platform or electronic media for the treatment of Amblyopia.
• Focus on the combination of ophthalmology research and
advanced display technology used to send different images to each
of the patients eyes
13

14. •French multi-national video game developer and publisher
headquartered in Paris
• Popular games: Assassin’s Creed, Battlefield 4
•Third largest independent video game publisher in the
world
• 2013 revenue of €1.007 billion
14
Established partnership with
international game developer

15. Pediatric Eye Disease
Investigator Group
• PEDIG is a collaborative network dedicated to facilitating multi-center clinical
research in strabismus, amblyopia and other eye disorders that affect children
• PEDIG is funded by the National Eye Institute (division of NIH)
• PEDIG is conducting a 500 patient comparing the efficacy of Amblyotech’s
therapy in a head-to-head study against patching – The study will be complete
in the first quarter of 2016.
15

16. 16
Amblyotech Team
Experienced and Diverse Skill Sets
Management
• Joseph Koziak | CEO
• Robert Derricotte | COO
• Dr. Robert Hess | CSO
• Mark Krauth | VP Sales
• Dr. Vidhya Subramanian |
Medical
• Leslie Pierce | Finance
• Mike Hopson | Board of
Directors
Key Consultants
• Mathieu Ferland - Ubisoft
• Luca Sergio- Ethis
HealthTech
• Art Spalding- TAMMNet
(Regulatory Consulting)
• Mike Boken- Bench Works
Consulting
• Ying Zhang- Market Research

17. 17
Binocuclear – The effective and compliant
treatment for Amblyopia